感染性疾病用药专栏
ZHOU Helong;YANG Xiaoming;HE Shengsong;ZHU Huabin;HUANG Huafang
2003, 22(12): 845-847.
Objective:To survey the therapeutic effect of lamivudine alone or in combination with oxymatrine in the treatment of chronic viral hepatitis B. Methods:76 patients with chronic viral hepatitis B were divided into 3 groups: A, B and C. Patients of group A (n=35) were given each 100 mg of lamivudine PO, q.d. for 12 consecutive months. Patients of group B (n=21) were subjected to lamivudine treatment as well at the same dosage as that of patients in group A. In the meantime, each of them was given 20 mg of oxymatrine PO, t.i.d.. The course of treatment lasted 6 months. Patients of group C (n=20) were treated with conventional hepatinica and symptomatic therapeutic measures, serving as controls. Changes in serum HBV replication markers and liver functions were dynamically monitored. Results:①At the end of the 3rd, 6th and 12th months of treatment, the rates of sera to turn negative for HBVDNA were 62.9%, 80.0% and 77.1%, respectively, in patients of group A, and 76.2%, 90.5% and 76.2%, respectively, in patients of group B. In the same time series, the rates of sera to turn negative for HBeAg were 28.6,%.34.3% and 42.9%, respectively, in patients of group A, and 38.1%, 47.6% and 42.9%, respectively, in patients of group B. The rates of sera to turn negtive for HBVDNA and HBeAg, in patients of group A and group B were significantly higher than those in patients of group C(P<0.05). However, differences of these rates between patients of group A and group B were insignificant(P>0.05). ②At the end of the 3rd, 6th and 12th months, the rates for serum ALT to be normalized were 37.1%, 65.7% and 71.4%, respectively, in patients of group A, and 42.9%, 66.7% and 81.0%, respectively, in patients of group B. At the end of the 12th month only, the rates for serum ALT to be normalized in patients of group A and group B were significantly higher than that of patients in group C(P<0.05). Conclusion:Lamivudine alone or in combination with oxymatrine was shown to exert a definite inhibotory effect on hepatitis B virus. Administration of the two drugs in combination was capable of improving the liver function and increasing the rates for serum HBVDNA and HBeAg to turn negative.